Eli Lilly has announced it will acquire three vaccine developers in a major push to strengthen its infectious disease portfolio, investing up to $3.8 billion. This acquisition spree includes the purchase of LimmaTech Biologics and Curevo, focusing on next-generation vaccines for common bacterial infections and shingles prevention. The company’s stock has edged up following the announcement, reflecting positive market sentiment around these developments. This move marks a significant step for Lilly as it seeks to expand its drug pipeline and delve back into vaccine research.